Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo, Thomas P C; Balasegaram, Manica; Beijnen, Jos H; de Vries, Peter J.
J Antimicrob Chemother
; 67(11): 2576-97, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22833634
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case.
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Oral miltefosine treatment in children with visceral leishmaniasis: a brief review
Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis.
Treatment of leishmaniasis with miltefosine: 2008 status.
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.